Valid for Submission
C50.121 is a billable diagnosis code used to specify a medical diagnosis of malignant neoplasm of central portion of right male breast. The code C50.121 is valid during the fiscal year 2022 from October 01, 2021 through September 30, 2022 for the submission of HIPAA-covered transactions.
The code C50.121 is applicable to male patients only. It is clinically and virtually impossible to use this code on a non-male patient.
The Medicare Code Editor (MCE) detects and reports errors in the coding of claims data. The following ICD-10 Code Edits are applicable to this code:
Diagnostic Related Groups - MS-DRG Mapping
|MS-DRG||MS-DRG Title||MCD||Relative Weight|
|582||MASTECTOMY FOR MALIGNANCY WITH CC/MCC||09||1.6416|
|583||MASTECTOMY FOR MALIGNANCY WITHOUT CC/MCC||09||1.5416|
The relative weight of a diagnostic related group determines the reimbursement rate based on the severity of a patient's illness and the associated cost of care during hospitalization.
Convert C50.121 to ICD-9 Code
The General Equivalency Mapping (GEM) crosswalk indicates an approximate mapping between the ICD-10 code C50.121 its ICD-9 equivalent. The approximate mapping means there is not an exact match between the ICD-10 code and the ICD-9 code and the mapped code is not a precise representation of the original code.
Information for Patients
Male Breast Cancer
Although breast cancer is much more common in women, men can get it too. It happens most often to men between the ages of 60 and 70.
Breast lumps usually aren't cancer. However, most men with breast cancer have lumps. Other breast symptoms can include
- Dimpled or puckered skin
- A red, scaly nipple or skin
- Fluid discharge
Risk factors for male breast cancer include exposure to radiation, a family history of breast cancer, and having high estrogen levels, which can happen with diseases like cirrhosis or Klinefelter syndrome.
Treatment for male breast cancer is usually a mastectomy, which is surgery to remove the breast. Other treatments include radiation, chemotherapy and/or hormone therapy.
NIH: National Cancer Institute
[Learn More in MedlinePlus]